Smartleaf Asset Management’s Vertex Pharmaceuticals VRTX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$2.01M Buy
4,540
+555
+14% +$259K 0.07% 244
2025
Q4
$1.81M Buy
3,985
+752
+23% +$324K 0.07% 256
2025
Q3
$1.28M Buy
3,233
+770
+31% +$322K 0.08% 268
2025
Q2
$1.09M Sell
2,463
-385
-14% -$177K 0.1% 239
2025
Q1
$1.4M Buy
2,848
+244
+9% +$114K 0.14% 170
2024
Q4
$1.04M Buy
2,604
+381
+17% +$177K 0.11% 209
2024
Q3
$1.03M Buy
2,223
+563
+34% +$270K 0.12% 183
2024
Q2
$785K Buy
1,660
+354
+27% +$154K 0.13% 182
2024
Q1
$545K Buy
1,306
+431
+49% +$182K 0.11% 209
2023
Q4
$356K Buy
+875
New +$323K 0.1% 211

Other funds holding VRTX

Smartleaf Asset Management's VRTX Position: Q1 2026 in Review

Smartleaf Asset Management increased its Vertex Pharmaceuticals (VRTX) stake by 14% in Q1 2026, buying an estimated $259K and bringing the position to 4,540 shares worth $2.01M. The position accounts for 0.07% of the portfolio, ranked #244.

Smartleaf Asset Management first reported a position in VRTX in Q4 2023 and has held it in 10 quarters since. 1,687 funds tracked by Wall St. Rank hold VRTX as of Q1 2026.

  • Smartleaf Asset Management held 4,540 shares of Vertex Pharmaceuticals worth $2.01M as of Q1 2026.
  • Smartleaf Asset Management bought 555 Vertex Pharmaceuticals shares in Q1 2026, an estimated $259K.
  • Vertex Pharmaceuticals made up 0.07% of Smartleaf Asset Management's portfolio in Q1 2026, its #244 holding.
  • Smartleaf Asset Management first reported a position in Vertex Pharmaceuticals in Q4 2023 and has held it in 10 quarters since.
  • 1,687 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2026.

Based on Smartleaf Asset Management's 13F filing for Q1 2026, filed 15 May 2026.